Connect with us

News

US biotech company raises seed round to advance therapies for endocrine disorders

HBMAT’s programmes aim to deliver precision therapies for endocrine disorders

Published

on

The US biotech company HBM Alpha Therapeutics (HBMAT) has completed seed financing to advance its novel antibody therapies to treat common endocrine disorders such as congenital adrenal hyperplasia and polycystic ovary syndrome.

The company was founded on the work of Harbour BioMed‘s antibody discovery and development capabilities, and expertise in the molecular pathogenesis and treatment of endocrine disorders of founder, Dr Joseph Majzoub.

HBMAT’s programmes aim to deliver precision therapies for endocrine disorders, targeting a pathway for CAH and PCOS.

CAH is a rare-autosomal recessive genetic disease with a defective CYP21A2 gene. Patients diagnosed with the condition have life-threatening deficiencies of glucocorticoid and mineralocorticoid, with limited treatment options and no new therapeutic modalities in over 50 years.

While the current standard of care is associated with inevitable treatment-related side effects, specifically cushing syndrome, caused by having too much of a hormone called cortisol in the body and hyperandrogenism.

HBMAT is developing HAT001 which focuses on treating hyperandrogenism without causing cushing syndrome.

According to the company’s website, HAT001 would effectively cause reversible pharmacologic adrenalectomy, converting CAH patient treatment into that for primary adrenal insufficiency, which can be treated with much lower, physiological doses of glucocorticoid.

As a common and chronic endocrine disorder, PCOS affects over 10 per cent women of reproductive age around the world and is the most common cause of anovulatory female infertility.

HBMAT is also developing HAT002 for PCOS, targeting a pathway shared with CAH. The financing will be used to advance the programmes into the clinical stage.

“I am very excited about this unique opportunity of developing antibody therapeutics for CAH, a rare genetic disease and PCOS impacting women’s health,” said Jingsong Wang, founder, chairman and CEO of Harbour BioMed.

“The company is thrilled to take these exciting programmes to the next level and translate this therapeutic antibody with very impressive biological functions into clinical benefits for patients with significant unmet medical needs.”

Dr Philip Reilly, a clinical geneticist and biotech entrepreneur, and board member of HBMAT, added: “I’ve worked closely with patient groups and tried to help those suffering from rare diseases over the past decades.

“HBMAT has already identified a clinical development candidate with excellent characteristics in preclinical functional activities including in vivo efficacy in various relevant animal models.

“I look forward to moving the development candidate into clinical trials and beyond.”

News

New survey to ‘amplify’ marginalised voices in healthcare decision-making

UK charities enter partnership to address gender gap and advocate for inclusive healthcare policies

Published

on

The gynaecological health charity Cysters and Endometriosis UK have announced a partnership to amplify women’s voice in healthcare decision-making.

Despite progress in healthcare data collection, there remains a gap in representing the experiences of marginalised groups, particularly for those impacted by conditions and diseases like endometriosis.

Decision-makers in Parliament and the NHS often rely on data and statistics to inform policy and resource allocation. However, these datasets may not accurately reflect the experiences of marginalised communities.

A recent report from Endometriosis UK that gathered data on the experiences of being diagnosed with endometriosis in the UK found that whilst the ethnicity of respondents who identified as ‘white’ was proportionate to the data collected in the Census 2021, the remaining data was not illustrative of the ethnic diversity of the UK, with 15 per cent of respondents choosing not to respond to the ethnicity question.

To address this gap and advocate for inclusive healthcare policies, Cysters and Endometriosis UK are launching a new survey initiative aimed at amplifying the voices of marginalised groups in healthcare decision-making.

“We know that the current statistics are not inclusive of all communities, particularly marginalised groups,” said Neelam Heera-Shergill, founder of Cysters.

“By encouraging those from marginalised communities to share their experiences through this survey, they will be helping us to advocate for the changes that are needed, backed by evidence from their communities.

“In addition to delving into the diagnosis journey for people of colour and the unique barriers they encounter. We aim for this research and findings to pave the way for additional funded research on all menstrual-related conditions affecting people of colour.”

The survey seeks to gather insights into the experiences of marginalised communities, particularly concerning conditions and diseases like endometriosis.

Participants are encouraged to share their experiences openly and honestly, knowing that their responses will contribute to shaping more inclusive healthcare policies.

Sarah Harris, a researcher at Cysters, said: “We urge everyone to participate in this survey and share it far and wide. Together, we can ensure that all voices are considered in the conversation surrounding healthcare policy and resource allocation.”

The survey is anonymous and takes approximately 15 minutes to complete. To participate, visit Delayed Diagnosis of Endometriosis Among People of Colour in the UK Survey.

To receive the Femtech World newsletter, sign up here.

Continue Reading

News

Menstrual care start-up launches period equity initiative across college campuses

The initiative is hoped to facilitate access to period care and educate students on the use of more sustainable products

Published

on

Cherie Hoeger, founder and CEO of Saalt

The US menstrual care start-up Saalt has launched a new initiative aimed at addressing period poverty and environmental sustainability.

The Period Equity Initiative aims to reduce 100 million tampons from the environment while combatting period poverty.

Institutions, including Harvard University, Vanderbilt University, Northwestern University, the University of Utah and the University of Nebraska, are already participating in the programme.

One in five female college students in the US have had to decide between buying period products and paying for other basic essentials like food and other bills according to a nationwide survey.

The initiative, a direct response to the demand for more units for student populations, underscores the issue of period poverty, which affects students across America, challenging the misconception that it is solely an “overseas problem”.

Saalt aims to make period care accessible and affordable through the subsidisation of reusable period products, such as cups, discs, and period underwear, to participating universities and their campus affiliates.

The project is hoped to not only facilitate access to period care, but also educate students on the use of more sustainable products, which are designed to be reused rather than discarded.

“Every day we hear from customers about how life-changing Saalt cups are for them,” said Cherie Hoeger, founder and CEO of Saalt.

“Creating period equity and managing the environmental impact created by disposables are pressing matters that demand urgent attention and innovative solutions.

“Through our Period Equity Initiative, we’re taking a proactive approach to tackle these challenges by leveraging our expertise and aligning with universities across America to make a big impact closer to home.”

The Period Equity Initiative, Hoeger added, furthers Saalt’s commitment to making period care more affordable, accessible and sustainable.

To receive the Femtech World newsletter, sign up here.

Continue Reading

News

Medical device start-up enters partnership with Bayer Switzerland

The collaboration is hoped to help “transform” gynaecological examinations

Published

on

The medical device start-up Aspivix has announced a partnership with Bayer Switzerland in an effort to “modernise” gynaecological procedures.

Aspivix has developed an innovative, suction-based cervical device designed as an alternative to the tenaculum, a surgical instrument commonly used in gynaecology for over a century.

The device aims to reduce pain and bleeding during transcervical procedures, including IUD placement.

Through the partnership with Bayer, Aspivix is now officially introducing Carevix in an effort to “transform” gynaecological examinations.

The collaboration is hoped to help bring the tool to market and offer women a more comfortable gynaecological experience, reducing the cases of pain associated with IUD procedures.

“We are excited to enter this partnership with Bayer (Schweiz) AG that truly emphasise the goal of empowering women to select the best contraceptive solution without worrying about potential pain and bleeding,” said Mathieu Horras, co-founder and CEO of Aspivix.

“The thorough research and clinical data behind Carevix guarantee a notable decrease in pain and bleeding, enhancing the experience of IUD adoption and placement, as well as various other gynaecological procedures for millions of women.”

The device, Horras added, provides an appealing alternative to the currently available tenaculum, filling an “important” unmet need.

Marco Gierten, Bayer Switzerland women’s healthcare lead, said: “As a globally trusted brand, Bayer remains committed to advancing solutions that provide significant benefits to patients.”

To receive the Femtech World newsletter, sign up here.

Continue Reading

Trending

Copyright © 2023 Aspect Publishing Ltd. All Rights Reserved.